MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $737, high $1308, with mid-point at $1016.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$1,016
Margin of safety
+28.6%
Confidence
79/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$725.17Price
Low $737.34
Mid $1,016.12
High $1,307.92
MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Immense scale forming an entrenched
Immense scale forming an entrenched oligopoly in US pharmaceutical distribution.
High barriers to entry due
High barriers to entry due to extreme capital and regulatory requirements.
Cycle upside
Aging demographics and expanded specialty drug approvals drive sustained volume growth.
Each scenario for MCK (MCK) carries a five-year price target, an explicit set of assumptions (growth, terminal multiple, margin path), and a probability weight calibrated against current visibility.
Probability weights start from a 25/50/25 default and are asymmetry-adjusted: when downside risk is elevated, base + bear gain weight; when visibility is high (long RPO, multi-year contracts), bull and base both gain.
Expected return is the probability-weighted average of the three scenario returns. The expected-value table reports the weighted price, weighted return, and asymmetry to help the reader compare risk-reward against the rating band.
When our composite fair value differs from private calibration references by more than 30%, the calibration-divergence diagnostic is run to identify which assumptions drive the gap; the result is summarised in the parent valuation surface.
FAQ
MCK — frequently asked questions
Based on our latest analysis, MCK looks meaningfully undervalued. The current price is $725 versus a composite fair-value midpoint of $1016 (range $737–$1308), which implies roughly 40.1% upside to the midpoint.
Our composite fair-value range for MCK is $737–$1308, with a midpoint of $1016. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for MCK's archetype.
Our current rating for MCK is Strong Buy with a confidence score of 79/100. MCK is rated Strong Buy at $725.17 versus the reconciled fair value midpoint of $1,016.12, implying +40.12% upside/downside. Confidence is separately disclosed at 79/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for MCK are: Major Retail Network Loss; Regulatory Margin Collapse; Resurgent Litigation. The single biggest risk is Major Retail Network Loss: The loss of a massive retail pharmacy network customer significantly impairs revenue volume and devastates operating leverage.
Our current rating for MCK is Strong Buy, issued with a confidence score of 79/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($737–$1308) versus the current price of $725.
MCK is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for MCK.